Allergy Therapeutics plc
Allergy Therapeutics plc, a commercial biotechnology company, focuses on the diagnosis and treatment of allergic disorders in Germany, Austria, United Kingdom, Netherlands, Switzerland, Italy, Spain, and internationally. The company sells injectable and sublingual allergen-specific immunotherapies, and offers treatment of pollen-related allergies, particularly to grasses, weeds, and trees, as wel… Read more
Allergy Therapeutics plc (AGYTF) - Total Assets
Latest total assets as of June 2025: $67.54 Million USD
Based on the latest financial reports, Allergy Therapeutics plc (AGYTF) holds total assets worth $67.54 Million USD as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Allergy Therapeutics plc - Total Assets Trend (2002–2025)
This chart illustrates how Allergy Therapeutics plc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Allergy Therapeutics plc - Asset Composition Analysis
Current Asset Composition (June 2025)
Allergy Therapeutics plc's total assets of $67.54 Million consist of 51.3% current assets and 48.7% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 26.0% |
| Accounts Receivable | $10.94 Million | 16.2% |
| Inventory | $13.91 Million | 20.6% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $1.28 Million | 1.9% |
| Goodwill | $4.56 Million | 6.8% |
Asset Composition Trend (2002–2025)
This chart illustrates how Allergy Therapeutics plc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Allergy Therapeutics plc's current assets represent 51.3% of total assets in 2025, an increase from 37.0% in 2002.
- Cash Position: Cash and equivalents constituted 26.0% of total assets in 2025, up from 0.6% in 2002.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 7.0% of total assets, a decrease from 49.0% in 2002.
- Asset Diversification: The largest asset category is inventory at 20.6% of total assets.
Allergy Therapeutics plc Competitors by Total Assets
Key competitors of Allergy Therapeutics plc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
Allergy Therapeutics plc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Strong asset utilization - Allergy Therapeutics plc generates 1.12x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Allergy Therapeutics plc is currently not profitable relative to its asset base.
Allergy Therapeutics plc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.93 | 1.63 | 3.03 |
| Quick Ratio | 0.42 | 1.01 | 2.47 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-2.65 Million | $ 12.94 Million | $ 36.94 Million |
Allergy Therapeutics plc - Advanced Valuation Insights
This section examines the relationship between Allergy Therapeutics plc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 8.21 |
| Latest Market Cap to Assets Ratio | 0.37 |
| Asset Growth Rate (YoY) | 4.2% |
| Total Assets | $67.54 Million |
| Market Capitalization | $25.30 Million USD |
Valuation Analysis
Below Book Valuation: The market values Allergy Therapeutics plc's assets below their book value (0.37 x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Allergy Therapeutics plc's assets grew by 4.2% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Allergy Therapeutics plc (2002–2025)
The table below shows the annual total assets of Allergy Therapeutics plc from 2002 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-06-30 | $67.54 Million | +4.19% |
| 2024-06-30 | $64.83 Million | -2.91% |
| 2023-06-30 | $66.77 Million | -9.26% |
| 2022-06-30 | $73.58 Million | -16.47% |
| 2021-06-30 | $88.09 Million | +2.16% |
| 2020-06-30 | $86.22 Million | +25.88% |
| 2019-06-30 | $68.50 Million | +34.27% |
| 2018-06-30 | $51.02 Million | -10.78% |
| 2017-06-30 | $57.18 Million | +0.89% |
| 2016-06-30 | $56.68 Million | +11.80% |
| 2015-06-30 | $50.70 Million | +78.53% |
| 2014-06-30 | $28.40 Million | -1.95% |
| 2013-06-30 | $28.96 Million | +4.36% |
| 2012-06-30 | $27.75 Million | -9.36% |
| 2011-06-30 | $30.62 Million | +5.17% |
| 2010-06-30 | $29.11 Million | +31.88% |
| 2009-06-30 | $22.08 Million | -4.77% |
| 2008-06-30 | $23.18 Million | -3.38% |
| 2007-06-30 | $23.99 Million | -36.66% |
| 2006-06-30 | $37.88 Million | +42.09% |
| 2005-06-30 | $26.66 Million | +137.32% |
| 2004-06-30 | $11.23 Million | +0.76% |
| 2003-06-30 | $11.15 Million | +15.22% |
| 2002-06-30 | $9.68 Million | -- |